BridgeMD
New treatment option for ARDS (Acute Respiratory Distress Syndrome)
Official title Effect of EIT-guided PEEP in ARDS Patients
ClinicalTrials.gov ID: NCT06990477
What this study is testing
- What it's testing
- Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 90
You may be able to join if
- Age≥18 years
- Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio...
- Diagnosis of ARDS less than 72 hours
You likely can't join if
- Expected to be mechanically ventilated for less than 48 hours
- Severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive MV
- Undrained pneumothorax or subcutaneous emphysema
- Contraindication to the use of EIT (pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps)
- Severe neuromuscular disease
- Hemodynamic instability
See the full eligibility criteria
- Age≥18 years
- Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O)
- Diagnosis of ARDS less than 72 hours
- Expected to be mechanically ventilated for less than 48 hours
- Severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive MV
- Undrained pneumothorax or subcutaneous emphysema
- Contraindication to the use of EIT (pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps)
- Severe neuromuscular disease
- Hemodynamic instability
- Contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome
- Severe other organs dysfunction with a low expected survival (7 days) or palliative care
- Severe liver disease (Child-Pugh Score ≥10)
- Pregnancy
- Refusal to sign the informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
- Shanghai, China Mainland, China
- Guangzhou, Guangdong, China
- Zhengzhou, Henan, China
- Hangzhou, Jiangsu, China
- Nanjing, Jiangsu, China
- Xuzhou, Jiangsu, China
- Nanchang, Jiangxi, China
- Xining, Qinghai, China
- Xian, Shanxi, China
- Quzhou, Zhejiang, China
- Beijing, China
- Hangzhou, China
- Shanghai, China
- Seoul, South Korea
- Taichung, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China; Shanghai, China Mainland, China; Guangzhou, Guangdong, China; Zhengzhou, Henan, China; Hangzhou, Jiangsu, China; Nanjing, Jiangsu, China and 10 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.